5/4/2021 4:11:12 PM
PerkinElmer Q1 GAAP EPS From Cont Ops $3.37 Vs $0.30 Last Year
4/29/2021 4:19:09 PM
PerkinElmer (PKI) Declares Quarterly Dividend of $ 0.07, Record Date 7/16/2021
4/13/2021 4:24:22 PM
PerkinElmer Expects Q1 Revenue Growth Of 98%
3/9/2021 8:04:04 AM
PerkinElmer Completes Acquisition Of Oxford Immunotec Global
3/4/2021 7:33:22 PM
PerkinElmer Says Prices Offering Of Senior Notes
2/23/2021 8:11:54 AM
PerkinElmer Says Changes COVID-19 Rapid Testing Landscape With Point Of Care Antigen Test For Mass Screening
2/22/2021 8:36:53 AM
PerkinElmer Provides Update On COVID-19 Valencia Branch Laboratory's Accreditation Process
2/2/2021 4:10:25 PM
PerkinElmer Q4 EPS $3.38 Vs. $0.58 Year Ago
1/28/2021 4:17:54 PM
PerkinElmer (PKI) Declares Quarterly Dividend of $ 0.07, Record Date 4/16/2021
1/14/2021 8:03:43 AM
PerkinElmer SARS-CoV-2 RT-PCR Assay Gets FDA EUA For Asymptomatic Testing
1/11/2021 6:04:54 AM
PerkinElmer Anticipates Q4 Reported And Organic Revenue Growth Of 66% And 63%, Respectively
1/7/2021 7:04:24 AM
PerkinElmer To Acquire Oxford Immunotec
11/12/2020 8:08:23 AM
PerkinElmer SARS-CoV-2 RT-PCR Assay Gets CE Mark For Saliva,Sample Pooling To Test Symptomatic &Asymptomatic Individuals
11/9/2020 8:07:15 AM
PerkinElmer: EUROIMMUN Launches Quantitative ELISA To Measure SARS-CoV-2 Antibodies Against Viral S1 Protein